Piramal Pharma Boosts Stake in Yapan Bio, Shares Climb

Piramal Pharma Ltd. shares surged over 3% on Tuesday, August 18, 2026, following the company’s announcement of completing an additional equity acquisition in Yapan Bio Pvt. Ltd. This transaction increased Piramal Pharma’s total shareholding in Yapan Bio to 74.00%.

The company acquired an additional 40.67% equity stake for approximately Rs 76 crore, transforming Yapan Bio from an associate company into a subsidiary. Yapan Bio operates as a contract development and manufacturing organization (CDMO), specializing in vaccines and biologics.

Key Acquisition Details and Market Performance

• Piramal Pharma’s previous stake in Yapan Bio: 33.33%
• Additional equity acquired: 40.67%
• Total shareholding post-acquisition: 74.00%
• Transaction value: Approximately Rs 76 crore
• Piramal Pharma share price open: Rs 200.10 on NSE
• Piramal Pharma intraday high: Rs 210.77 on NSE
• Piramal Pharma closing trade: 2.65% higher at Rs 210.15 apiece

Piramal Pharma stated that this strategic acquisition fully integrates Yapan Bio’s advanced large molecule capabilities into its existing service offerings. This move is expected to enhance the company’s capacity to develop and scale complex biologic therapies.

Yapan Bio Financials and Piramal Pharma’s Outlook

Yapan Bio Pvt. Ltd. reported varied revenues from operations over recent fiscal years. For FY2024, its revenue stood at Rs 26.91 crore, increasing to Rs 54.40 crore in FY2025, before declining to Rs 26.34 crore for FY2026.

• Piramal Pharma’s market capitalization: Rs 27,945.00 crore
• One-month stock return: 17%
• Year-to-date stock return: 24%
• One-year stock return: 9%

The integration of Yapan Bio’s specialized CDMO services into Piramal Pharma’s portfolio is aimed at bolstering its position in the large molecule segment, supporting future growth in complex biologic development.